ARCHIVES

FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings.

This article is from The Cancer Letter archive.

Vol. 34 No. 31 | August 8, 2008

Download PDF Visit The Full Archive

Related Articles

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

February 24, 2006

Blacks Half As Likely To Get Surgery For Esophageal Cancer

January 28, 2005

Arizona Cancer Center Seeks NCI Recognition As Comprehensive

May 29, 1987

DRCCA Board Changes Center Core Grants Guidelines To Permit Payment for Control Program Directors

October 29, 1982

Tracor Could Earn $186,000 As Prime Contractor On Carcinogenesis Bioassay

April 26, 1974

NCI Workshop Summary “Incomplete,” Kopans Writes In Letter

April 16, 1993